MTOR and hepatocellular carcinoma: Despite this strong theoretical basis for using the mTOR inhibitor everolimus to treat HCC, the final results from a phase III trial did not suggest any trend of prolonged OS (everolimus vs. placebo, 7.6 vs. 7.3 months) [44].